Table 1.
Regular use and starting visit of cholinesterase inhibitors and memantine over the DPS follow-up
| Dementia Medication | Baseline (n=327) |
Visit 2 (n=216) |
Visit 3 (n=140) |
Visit 4 (n=110) |
Visit 5 (n=84) |
Visit 6 (n=60) |
Visit 7 (n=35) |
Visit 8 (n=23) |
Visit 9 (n=16) |
Visit 10 (n=11) |
Visit 11 (n=3) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Cholinesterase Inhibitor Only | |||||||||||
| Use | 32 (9.8%) | 33 (15.3%) | 27 (19.3%) | 22 (20.0%) | 14 (16.7%) | 7 (11.7%) | 2 (5.7%) | 1 (4.4%) | 0 | 0 | 0 |
| Visit Started | 32 (9.8%) | 14 (6.5%) | 7 (5.0%) | 4 (3.6%) | 0 | 1 (1.7%) | 0 | 0 | 0 | 0 | 0 |
| Memantine Only | |||||||||||
| Use | 1 (0.3%) | 2 (0.9%) | 3 (2.1%) | 2 (1.8%) | 2 (2.4%) | 2 (3.3%) | 1 (2.9%) | 0 | 1 (6.3%) | 0 | 0 |
| Visit Started | 1 (0.3%) | 2 (0.9%) | 2 (1.4%) | 1 (0.9%) | 1 (1.2%) | 1 (1.7%) | 0 | 0 | 0 | 0 | 0 |
| Both | |||||||||||
| Use | 3 (0.9%) | 3 (1.4%) | 7 (5.0%) | 8 (7.3%) | 9 (10.7%) | 8 (13.3%) | 4 (11.4%) | 2 (8.7%) | 2 (12.5%) | 2 (18.2%) | 1 (33.3%) |
| Visit Started | 3 (0.9%) | 2 (0.9%) | 6 (4.2%) | 2 (1.8%) | 4 (4.8%) | 2 (3.3%) | 0 | 0 | 1 (6.3%) | 0 | 0 |
| Any Medication Use | 36 (11.0%) | 38 (17.6%) | 37 (27.2%) | 32 (29.0%) | 25 (29.8%) | 17 (28.3%) | 7 (20.6%) | 3 (13.6%) | 3 (18.8%) | 2 (18.2%) | 1 (33.3%) |